TheraRadar
← Back
Data updated: Jul 17, 2026

ALEMBIC GLOBAL

Generics

ALEMBIC GLOBAL is a generic drug manufacturer focused on Cardiovascular, Respiratory.

2021
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

ALEMBIC GLOBAL's Key Drugs

ALEMBIC GLOBAL's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

ALEMBIC GLOBAL's Recent FDA Approvals

New NDA/BLA approvals for ALEMBIC GLOBAL over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ALEMBIC GLOBAL's Therapeutic Areas

ALEMBIC GLOBAL's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Respiratory. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 50%
1 drugs
Respiratory 50%
1 drugs

ALEMBIC GLOBAL's Top Competitors

ALEMBIC GLOBAL's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Bayer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

ALEMBIC GLOBAL Pipeline Snapshot

Active clinical trials for ALEMBIC GLOBAL across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling